SUNLOC75.50

Sunil Healthcare Limited

· Pharma & Health
₹ CrorePeersBPLPHARMAJENBURPHKPLMAKERSLNOVARTINDPARNAXLABSGRLSHUKRAPHAR
Comp Set
In ₹ Crore except Per Share
Latest Annual
SUNLOC
FY24
BPLPHARMA
FY23
JENBURPH
FY26
KPL
FY24
Peer
Median
Valuation — at last close
P/E37.02×37.02×
Growth
Revenue CAGR 3Y7.26%7.26%
Revenue CAGR 5Y9.07%9.07%
Net Income CAGR 3Y12.18%12.18%
Profitability
EBITDA Margin4.53%9.80%23.81%21.69%21.69% -79%
Net Income Margin-1.98%11.16%20.59%15.88% -112%
Return on Common Equity-2.42%12.74%12.74% -119%
Return on Capital Employed-1.87%19.18%19.18% -110%
Return on Assets-1.09%7.90%15.37%11.63% -109%
Credit & Quality
Total Debt/Equity0.89×0.04×0.43×0.23× +279%
Interest Coverage-0.35×7.10×4.54×5.82× -106%
Scale — latest FY
Revenue / Total Income₹90.2 Cr₹218 Cr₹169 Cr₹307 Cr₹218 Cr -59%
Net Income−₹1.8 Cr₹24.3 Cr₹34.7 Cr₹29.5 Cr -106%
Total Assets₹164 Cr₹308 Cr₹226 Cr₹398 Cr₹308 Cr -47%
EPS₹-1.74₹42.14₹42.14 -104%
◆ best value in the comp set per metric · Δ = subject vs median of the other companies.
« ‹ › »Latest: FY24 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreementXBRL cross-verified ✓ 85%.